文献速递中枢神经肿瘤放疗

复发性胶质母细胞瘤再程放疗的1期剂量递增试验

A Phase 1 Dose-Escalation Trial of Reirradiation for Patients With Recurrent Glioblastoma.
PubMed 文献 · Pract Radiat Oncol · 2026-02-04

该1期剂量递增试验采用「3+3」设计,在14例复发性胶质母细胞瘤患者中评估再程放疗的最大耐受剂量。

要点

  • 复发性胶质母细胞瘤再程放疗的最大耐受剂量为4200 cGy/12次。
  • 各剂量水平均未观察到剂量限制性毒性。

核心结论

  • 复发性胶质母细胞瘤再程放疗的最大耐受剂量为4200 cGy/12次。

研究设计与样本

  • 1期剂量递增试验采用「3+3」设计,纳入14例组织学证实的复发性胶质母细胞瘤患者。
  • 入组条件包括Karnofsky体能状态评分≥70,且距标准放化疗结束>12个月。

主要发现

  • 14例患者中男性占64%,中位Karnofsky体能状态评分80(范围70-90),中位年龄54岁(范围38-65)。
  • DL1、DL2、DL3分别入组3、6、5例;从初始放疗结束到再程放疗结束的中位时间为47.2个月(范围12.6-93.5个月)。
  • 中位无进展生存期为5.09个月,DL1、DL2、DL3分别为3.5、7.2、5.2个月。
  • 中位总生存期为10.3个月,DL1、DL2、DL3分别为6.1、14.4、13.3个月。
  • DL1和DL2未观察到治疗相关毒性;DL3中5例有3例出现无 prior 影像学肿瘤证据的神经功能下降,被判定为3级治疗相关毒性。

关键数值与推荐

  • 最大耐受剂量为4200 cGy/12次。
  • 各剂量水平均未观察到剂量限制性毒性。

临床怎么用

  • 对于距标准放化疗>12个月、体能状态良好的复发性胶质母细胞瘤患者,再程放疗可考虑4200 cGy/12次。
  • 再程放疗期间及治疗后需关注神经功能变化,尤其在高剂量水平时。

局限性

  • 样本量小,共14例患者。
  • 各剂量水平入组例数少(DL1 3例、DL2 6例、DL3 5例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A dose-escalation trial of reirradiation (reRT) was conducted in patients with a diagnosis of recurrent glioblastoma (rGBM) to increase the total overall dose given to the tumor without increasing toxicity. The primary objective of this study was to establish the maximum tolerated dose (MTD) for reRT in patients with rGBM. METHODS AND MATERIALS: A phase 1 dose-escalation study using a "3 plus 3" design aimed at identifying reRT MTD with secondary study endpoints of overall survival, progression-free survival, Health-Related Quality of Life, and neurocognitive outcomes. Patients with histologically proven rGBM, Karnofsky Performance Status ≥70, and >12 months since standard chemoradiation, were enrolled in the study. Patients received daily radiation therapy, 5 fractions per week, with dose levels (DLs) (total radiation dose [Gy]/number fractions): DL1 1(35/10), DL2 (42/12), and DL3 (49/14). Response and progression were defined as per Response Assessment in Neuro-Oncology criteria. Neurocognition and patient-reported outcomes were obtained before reRT, at completion of treatment and at follow-up intervals. RESULTS: Fourteen patients were enrolled (64% male, median Karnofsky Performance Status 80 [range, 70-90], median age 54 [range, 38-65]) in DL1(3), DL2(6), and DL3(5). The median time between upfront radiation therapy to completion of reRT was 47.2 months (range, 12.6-93.5 months) with patients enrolled from 2016 to 2022. Median progression-free survival was 5.09 months (3.5, 7.2, and 5.2 months for DL 1, 2, and 3, respectively). Overall survival was 10.3 months (6.1, 14.4, and 13.3 months for DL 1, 2, and 3, respectively). No treatment-related toxicity was observed for DLs 1 and 2. In DL3, 3 of 5 patients experienced neurologic decline without prior radiographic evidence of tumor and were therefore designated as grade 3 treatment-related toxicity. However, no dose-limiting toxicity was observed at any DL. CONCLUSIONS: Results of the trial reveal 4200 cGy in 12 fractions as the MTD for the group of patients with rGBM.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Mathen P, Krauze AV, Rowe L, et al. A Phase 1 Dose-Escalation Trial of Reirradiation for Patients With Recurrent Glioblastoma. Pract Radiat Oncol. 2026. PMID: 41651156. doi:10.1016/j.prro.2025.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。